Do analysts rate CNSP or PTPI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CNSP or PTPI more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -204.25% -141.87% Petros Pharmaceuticals N/A -78.22% -23.50%

Do analysts rate UG or CNSP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score United-Guardian 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer MIRA or CNSP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, MIRA or CNSP?

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MIRA Pharmaceuticals N/A N/A -$10.44M -$1.24 N/A CNS Pharmaceuticals N/A N/A -$15.85M -$23.59 N/A

Is MIRA or CNSP more profitable?

MIRA Pharmaceuticals' return on equity of -106.95% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -106.95% -104.18% CNS Pharmaceuticals N/A -204.25% -141.87%

Do analysts recommend CNSP or TAOX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate CNSP or BGM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, CNSP or BGM?

CNS Pharmaceuticals has higher earnings, but lower revenue than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CNS Pharmaceuticals N/A N/A -$15.85M -$23.59 N/A BGM Group $37.92M 0.67 -$19.94M N/A N/A

Is CNSP or BGM more profitable?

BGM Group's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -204.25% -141.87% BGM Group N/A N/A N/A

CNS Pharmaceuticals (CNSP) Competitors

$5.84 0.00 (0.00%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$5.75 -0.09 (-1.61%)

As of 04:00 AM Eastern

Compare

CNSP vs. PTPI, UG, MIRA, TAOX, and BGM

Should you buy CNS Pharmaceuticals stock or one of its competitors? CNS Pharmaceuticals's main competitors and comparable companies include Petros Pharmaceuticals (PTPI), United-Guardian (UG), MIRA Pharmaceuticals (MIRA), Synaptogenix (TAOX), and BGM Group (BGM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, CNS Pharmaceuticals had 2 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 2 mentions for CNS Pharmaceuticals and 0 mentions for Petros Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 1.44 beat Petros Pharmaceuticals' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
Petros Pharmaceuticals	Neutral

Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$0.36	N/A

CNS Pharmaceuticals has a beta of 3.06, indicating that its stock price is 206% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market.

14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 1.8% of CNS Pharmaceuticals shares are held by insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-204.25%	-141.87%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Petros Pharmaceuticals beats CNS Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to United-Guardian?

United-Guardian (NASDAQ:UG) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

United-Guardian has a net margin of 22.01% compared to CNS Pharmaceuticals' net margin of 0.00%. United-Guardian's return on equity of 22.24% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United-Guardian	22.01%	22.24%	19.12%
CNS Pharmaceuticals	N/A	-204.25%	-141.87%

23.2% of United-Guardian shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 29.0% of United-Guardian shares are owned by insiders. Comparatively, 1.8% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

United-Guardian has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United-Guardian	$10.55M	3.12	$2.11M	$0.54	13.28
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A

In the previous week, CNS Pharmaceuticals had 1 more articles in the media than United-Guardian. MarketBeat recorded 2 mentions for CNS Pharmaceuticals and 1 mentions for United-Guardian. United-Guardian's average media sentiment score of 1.89 beat CNS Pharmaceuticals' score of 1.44 indicating that United-Guardian is being referred to more favorably in the media.

Company	Overall Sentiment
United-Guardian	Very Positive
CNS Pharmaceuticals	Positive

United-Guardian has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.06, meaning that its stock price is 206% more volatile than the broader market.

Summary

United-Guardian beats CNS Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to MIRA Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A

In the previous week, CNS Pharmaceuticals had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for CNS Pharmaceuticals and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.89 beat CNS Pharmaceuticals' score of 1.44 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Very Positive
CNS Pharmaceuticals	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MIRA Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.06, indicating that its stock price is 206% more volatile than the broader market.

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 19.9% of MIRA Pharmaceuticals shares are owned by company insiders. Comparatively, 1.8% of CNS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MIRA Pharmaceuticals' return on equity of -106.95% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%
CNS Pharmaceuticals	N/A	-204.25%	-141.87%

Summary

MIRA Pharmaceuticals beats CNS Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Synaptogenix?

CNS Pharmaceuticals (NASDAQ:CNSP) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

In the previous week, CNS Pharmaceuticals and CNS Pharmaceuticals both had 2 articles in the media. CNS Pharmaceuticals' average media sentiment score of 1.44 beat Synaptogenix's score of 0.76 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
Synaptogenix	Positive

CNS Pharmaceuticals has a beta of 3.06, suggesting that its stock price is 206% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 1.8% of CNS Pharmaceuticals shares are owned by company insiders. Comparatively, 2.7% of Synaptogenix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CNS Pharmaceuticals has higher earnings, but lower revenue than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A
Synaptogenix	$300K	97.24	-$28.74M	-$3.85	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CNS Pharmaceuticals has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-204.25%	-141.87%
Synaptogenix	-2,153.97%	-128.51%	-97.54%

Summary

CNS Pharmaceuticals beats Synaptogenix on 6 of the 11 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to BGM Group?

CNS Pharmaceuticals (NASDAQ:CNSP) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BGM Group's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-204.25%	-141.87%
BGM Group	N/A	N/A	N/A

CNS Pharmaceuticals has a beta of 3.06, indicating that its share price is 206% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

In the previous week, CNS Pharmaceuticals and CNS Pharmaceuticals both had 2 articles in the media. CNS Pharmaceuticals' average media sentiment score of 1.44 beat BGM Group's score of 0.67 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
BGM Group	Positive

14.0% of CNS Pharmaceuticals shares are held by institutional investors. 1.8% of CNS Pharmaceuticals shares are held by insiders. Comparatively, 58.7% of BGM Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CNS Pharmaceuticals has higher earnings, but lower revenue than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A
BGM Group	$37.92M	0.67	-$19.94M	N/A	N/A

Summary

CNS Pharmaceuticals and BGM Group tied by winning 4 of the 8 factors compared between the two stocks.

Get CNS Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNSP vs. The Competition

Export

Metric	CNS Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.53M	$12.45B	$7.15B	$12.84B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-0.25	799.77	275.25	25.35
Price / Sales	N/A	756.98	640.15	90.72
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	0.80	10.40	10.37	6.21
Net Income	-$15.85M	$2.85B	$3.50B	$358.54M
7 Day Performance	0.85%	-3.60%	-3.30%	-2.39%
1 Month Performance	5.80%	0.49%	-0.84%	-3.39%
1 Year Performance	-20.97%	3.58%	23.55%	8.81%

CNS Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNSP CNS Pharmaceuticals	1.3742 of 5 stars	$5.84 flat	N/A	-21.0%	$8.53M	N/A	N/A	5	Short Interest Decrease High Trading Volume
PTPI Petros Pharmaceuticals	N/A	$0.01 +5.0%	N/A	-77.9%	$187K	$5.11M	N/A	20	Gap Up
UG United-Guardian	1.9786 of 5 stars	$7.12 -0.3%	N/A	-8.1%	$32.78M	$10.55M	13.19	20	Positive News
MIRA MIRA Pharmaceuticals	0.9708 of 5 stars	$0.78 +1.6%	N/A	-46.6%	$32.10M	N/A	N/A	2	Positive News Gap Up
TAOX Synaptogenix	0.1917 of 5 stars	$4.01 +3.4%	N/A	-37.2%	$29.07M	$300K	N/A	4	Analyst Downgrade Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNSP) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CNS Pharmaceuticals (CNSP) Competitors

CNSP vs. PTPI, UG, MIRA, TAOX, and BGM

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Summary

How does CNS Pharmaceuticals compare to United-Guardian?

Summary

How does CNS Pharmaceuticals compare to MIRA Pharmaceuticals?

Summary

How does CNS Pharmaceuticals compare to Synaptogenix?

Summary

How does CNS Pharmaceuticals compare to BGM Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP vs. The Competition

CNS Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CNS Pharmaceuticals (CNSP) Competitors

CNSP vs. PTPI, UG, MIRA, TAOX, and BGM

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Does the media prefer CNSP or PTPI?

Which has better earnings & valuation, CNSP or PTPI?

Which has more risk and volatility, CNSP or PTPI?

Do institutionals & insiders hold more shares of CNSP or PTPI?

Is CNSP or PTPI more profitable?

Do analysts rate CNSP or PTPI?

Summary

How does CNS Pharmaceuticals compare to United-Guardian?

Do analysts rate UG or CNSP?

Is UG or CNSP more profitable?

Do institutionals and insiders have more ownership in UG or CNSP?

Which has better valuation & earnings, UG or CNSP?

Does the media refer more to UG or CNSP?

Which has more risk & volatility, UG or CNSP?

Summary

How does CNS Pharmaceuticals compare to MIRA Pharmaceuticals?

Which has higher valuation and earnings, MIRA or CNSP?

Does the media refer more to MIRA or CNSP?

Do analysts prefer MIRA or CNSP?

Which has more risk and volatility, MIRA or CNSP?

Do institutionals and insiders hold more shares of MIRA or CNSP?

Is MIRA or CNSP more profitable?

Summary

How does CNS Pharmaceuticals compare to Synaptogenix?

Does the media refer more to CNSP or TAOX?

Which has more volatility & risk, CNSP or TAOX?

Do insiders & institutionals hold more shares of CNSP or TAOX?

Which has higher valuation & earnings, CNSP or TAOX?

Do analysts recommend CNSP or TAOX?

Is CNSP or TAOX more profitable?

Summary

How does CNS Pharmaceuticals compare to BGM Group?

Do analysts rate CNSP or BGM?

Is CNSP or BGM more profitable?

Which has more risk and volatility, CNSP or BGM?

Does the media prefer CNSP or BGM?

Do institutionals & insiders believe in CNSP or BGM?

Which has better earnings and valuation, CNSP or BGM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP vs. The Competition

CNS Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools